These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 277237)

  • 1. The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse.
    Hirst DG; Vojnovic B; Stratford IJ; Travis EL
    Br J Cancer Suppl; 1978 Jun; 3():237-41. PubMed ID: 277237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral electrophysiological parameters in mice treated with misonidazole.
    Von Burg R; Conroy PJ; Passalacqua W
    Br J Cancer; 1979 Jul; 40(1):134-43. PubMed ID: 454559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in nerve conduction velocity in the mouse after acute and chronic administration of nitroimidazoles.
    Hirst DG; Vojnovic B; Hobson B
    Br J Cancer; 1979 Feb; 39(2):159-67. PubMed ID: 435365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electroneurographic investigations of misonidazole polyneuropathy.
    Mamoli B; Wessely P; Kogelnik HD; Müller M; Rathkolb O
    Eur Neurol; 1979; 18(6):405-14. PubMed ID: 232682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity of misonidazole in rats following intravenous administration.
    Graziano MJ; Henck JW; Meierhenry EF; Gough AW
    Pharmacol Res; 1996 Jun; 33(6):307-18. PubMed ID: 8971952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of artificial lung metastases by misonidazole.
    Rockwell S; Nierenburg M; Irvin CG
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1395-8. PubMed ID: 6469763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ; Hei TK
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misonidazole neurotoxicity in the mouse: evaluation of functional, pharmacokinetic, electrophysiologic and morphologic parameters.
    Conroy PJ; Von Burg R; Passalacqua W; Penney DP; Sutherland RM
    Int J Radiat Oncol Biol Phys; 1979 Jul; 5(7):983-91. PubMed ID: 511631
    [No Abstract]   [Full Text] [Related]  

  • 9. The hypoxic cell sensitizer programme in the United States.
    Phillips TL; Wasserman TH; JohnsonRJ ; Gomer CJ; Lawrence GA; Levine ML; Sadee W; Penta JS; Rubin DJ
    Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
    Roberts JT; Bleehen NM; Workman P; Walton MI
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
    Hei TK; Geard CR; Osmak RS; Hall EJ
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acute and chronic misonidazole administration on peripheral-nerve electrophysiology in mice.
    Conroy PJ; Von Burg R; Penney DP; Passalacqua W; Sutherland RM
    Br J Cancer; 1980 Apr; 41(4):523-8. PubMed ID: 7387850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The demonstration of in vivo misonidazole tumour toxicity using post radiation hypoxia.
    Gomer CJ; Johnson RJ; Hetzel FW; Lawrence G
    Br J Cancer Suppl; 1978 Jun; 3():228-31. PubMed ID: 277234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
    Palcic B; Faddegon B; Skarsgard LD
    Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Radiosensitizer: hypoxic cell radiosensitizer].
    Mori T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo radiosensitizing effect of nitroimidazole derivative KIN-804.
    Tada T; Nakajima T; Onoyama Y; Murayama C; Mori T; Nagasawa H; Hori H; Inayama S
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):601-5. PubMed ID: 8005823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo radiosensitization by 2-nitroimidazoles more electron-affinic than misonidazole.
    Brown DM; Yu NY; Brown JM; Lee WW
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):435-8. PubMed ID: 7107364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural and ultrastructural studies of desmethylmisonidazole-induced neurotoxicity in mice.
    Chao CF; Subjeck JR; Johnson RJ
    Br J Radiol; 1983 Jan; 56(661):27-31. PubMed ID: 6821740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.